
    
      For patients with ET: To obtain a preliminary estimate of efficacy of imetelstat, as measured
      by best hematologic response within the first year of therapy in patients with ET who have
      failed or are intolerant to at least one prior therapy, or who have refused standard therapy.

      For patients with PV: To obtain a preliminary estimate of efficacy of imetelstat, as measured
      by maintenance of Hct < 45% in men and < 42% in women (or pre-specified Hct count that is
      tolerable) without phlebotomy or myelosuppressive therapy within the first year of therapy in
      patients with PV who have failed or are intolerant to at least one prior therapy, or who have
      refused standard therapy.
    
  